Nov-2021 Practical Management of Cardiovascular Risk Factors in Prostate Cancer Patients
Speakers:
Dr Hilary Glen – Consultant in Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
Dr Sivatharshini Ramalingam – Cardio-oncology GPwSI, Oxted Health Centre, The Royal Brompton Hospital, UK
In this session, organised and funded by Ferring Pharmaceuticals, speakers walked the audience members through studies between GnRH agonists and antagonists in CVD outcomes, including real world evidence in the UK primary care database. Dr. Glen then shed light on clinical practice of using GnRH agonists and GnRH antagonist in Scotland, where Degarelix was approved in 2020 to treat patients with history of stroke, TIA, MI etc.
